Hyperglycemia-induced oxidative stress affects multiple signal transduction and metabolic pathways. One of them is poly(ADP-ribosyl)ation induced by hydroxyl and superoxide radicals and peroxynitrite- stimulated DNA single-strand breakage. The OVERALL HYPOTHESIS of this proposal is that activation of endothelial and Schwann cell poly(ADP-ribose)synthetase (PARS), associated with NAD depletion, energy failure and, potentially, exacerbation of oxidative stress, contributes to neurovascular dysfunction, nerve conduction deficits, impaired neurotrophic support and morphological changes of peripheral diabetic neuropathy (PDN). The RATIONALE is based on the: 1) key role of oxidative stress in nerve blood flow (NBF), conduction and nerve growth factor (NGF) deficits of PDN; 2) key role of poly(ADP-ribosyl)ation in free radical damage in numerous pathologies (e.g. cardiovascular and neurodegenerative diseases, inflammation) associated with oxidative stress; 3) presence of PARS in endothelial and Schwann cells; 4)presence of DNA single-strand breaks after a short (endothelial cells) and prolonged (Schwann cells) exposure to hyperglycemia; 5) evidence of PARS activation in endothelial cells in short-term diabetes and recent demonstration of its key role in diabetes-induced endothelial dysfunction, and 6) applicant's preliminary data demonstrating correction of diabetes-induced motor and sensory nerve conduction velocities (MNCV and SNCV) and energy failure by two specific structurally diverse PARS inhibitors, 3-aminiobenzamide (3-AB) and 1,5-isoquinolinediol (ISO). The EXPERIMENTAL APPROACH will include in vivo evaluation of PARS inhibitors on NBF, conduction, bioenergetics, oxidative stress and nerve growth factor (NGF) abundance in early DN, and on these measures plus nerve morphometry in advanced PDN in the rat model, comparison of PDN in PARS-deficient (+/- or-/-) mice and the wild-type, and the studies of the role of PARS in hyperglycemia-induced apoptosis in vasa nervorum and endothelial cells.
The SPECIFIC AIMS are 1) evaluate 3-AB, ISO and PJ34 (a novel potent PARS inhibitor) on NBF, MNCV, SNCV, bioenergetics, oxidative stress and NGF levels in early DN (rats with 6-wk diabetes); 2) evaluate PJ34 on these and morphometric indices in advanced DN (rats with 8-mo diabetes); 3) compare PDN in PARS-deficient (+/- or -/- mice) and the wild-type; and 4) evaluate 3-AB, ISO and PJ34 on hyperglycemia-induced apoptosis in vasa nervorum and endothelial cells. The studies are of direct relevance to the pathogenesis of PDN and may provide the rationale for development of PARS inhibitors for its prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01DK059809-02
Application #
6654922
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2002-09-15
Project End
2004-01-31
Budget Start
2003-07-01
Budget End
2004-01-31
Support Year
2
Fiscal Year
2003
Total Cost
$88,460
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Drel, Viktor R; Pacher, Pal; Stavniichuk, Roman et al. (2011) Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice. Int J Mol Med 28:629-35
Stevens, M J; Li, F; Drel, V R et al. (2007) Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther 320:458-64
Obrosova, Irina G; Mabley, Jon G; Zsengeller, Zsuzsanna et al. (2005) Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 19:401-3
Obrosova, Irina G (2005) Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 7:1543-52
Obrosova, Irina G; Drel, Viktor R; Pacher, Pal et al. (2005) Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 54:3435-41
Obrosova, Irina G; Pacher, Pal; Szabo, Csaba et al. (2005) Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 54:234-42
Li, Fei; Obrosova, Irina G; Abatan, Omorodola et al. (2005) Taurine replacement attenuates hyperalgesia and abnormal calcium signaling in sensory neurons of STZ-D rats. Am J Physiol Endocrinol Metab 288:E29-36
Li, Fei; Drel, Viktor R; Szabo, Csaba et al. (2005) Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 54:1514-22
Li, F; Szabo, C; Pacher, P et al. (2004) Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 47:710-7
Obrosova, Irina G; Li, Fei; Abatan, Omorodola I et al. (2004) Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53:711-20

Showing the most recent 10 out of 11 publications